Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiology Societies Urge Registry For Left-Atrial Appendage Closure Devices

This article was originally published in The Gray Sheet

Executive Summary

The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.

You may also be interested in...



LAA Closure Devices: Cardiology Societies Weigh In

In June 2015, three cardiology societies issued a clinical overview on implantation of left atrial appendage closure devices that is the first in a series of documents highlighting the critical issues that need to be addressed in order to integrate these new technologies into clinical practice.

Policy Briefs: What's New From FDA And CMS

Updates include an FDA safety communication for the Lariat suture device addressing use for left atrial appendage closure, new FDA draft guidance documents, and CMS proposals to cut radiation therapy payments and launch new payment models for hip and knee replacements.

National Medicare Analysis Opened For Watchman Device

CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel